Fujian Cancer Hospital: all 162 studies

Page 1 of 2. Open to participants first (92), then studies with results posted, then the rest; newest registration first within each.

• Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast CancerRecruitingNCT07880600
• Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingNCT07766772Phase 2
• Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLCEnrolling by invitationNCT07738367Phase 2
• Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast CancerRecruitingNCT07702708
• Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast CancerNot yet recruitingNCT07691333Phase 2
• A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity Reaction and Its Correlation With BiomarkersNot yet recruitingNCT07613905Not applicable
• A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical CancerNot yet recruitingNCT07613567Phase 3
• Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyRecruitingNCT07581834Phase 2
• Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine CreamNot yet recruitingNCT07492654Phase 4
• SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell CarcinomaNot yet recruitingNCT07470840Phase 2
• Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal CancerRecruitingNCT07469306Phase 2
• Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line TreatmentRecruitingNCT07467330Phase 3
• CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction ChemotherapyNot yet recruitingNCT07399158
• Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07388836Phase 2
• MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPCRecruitingNCT07331428Phase 2
• Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)RecruitingNCT07320105Phase 4
• Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune IntoleranceNot yet recruitingNCT07313202Phase 2
• Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase IINot yet recruitingNCT07310771Phase 2
• The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuvant/Conversion Immunotherapy in Patients With Primary Resectable Liver CancerNot yet recruitingNCT07306481Not applicable
• Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal CarcinomaNot yet recruitingNCT07268690Phase 3
• SKB264 Plus QL1706 in Recurrent or Metastatic Cervical CancerRecruitingNCT07256236Phase 2
• A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal CarcinomaNot yet recruitingNCT07252375Phase 2
• Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 StudyNot yet recruitingNCT07243418Phase 2
• Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the EsophagealNot yet recruitingNCT07155122Phase 2
• Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical TrialRecruitingNCT07142122Not applicable
• Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsNot yet recruitingNCT07101159Phase 2
• Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal CarcinomaNot yet recruitingNCT07088484
• Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRCNot yet recruitingNCT07070713Phase 2
• A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and ChemotherapyNot yet recruitingNCT07069270Phase 2
• Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)RecruitingNCT07055399Phase 2
• Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or SurgeryNot yet recruitingNCT07046221Phase 2
• SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06979986Not applicable
• Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06793917Phase 3
• PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLMRecruitingNCT06788171Phase 2
• SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver MetastasesRecruitingNCT06787183Phase 2
• A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung CancerNot yet recruitingNCT06786312Phase 2
• Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal CancerNot yet recruitingNCT06775756Phase 3
• A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.Not yet recruitingNCT06746545Phase 2
• Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06692270Phase 2
• A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingNCT06654947Phase 2
• A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung CancerNot yet recruitingNCT06614621Phase 2
• Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian CancerNot yet recruitingNCT06600841Phase 2
• Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal CarcinomaNot yet recruitingNCT06572293Not applicable
• SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular CarcinomaNot yet recruitingNCT06538935Phase 2
• Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative GenesNot yet recruitingNCT06490913Phase 2
• Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06468670Phase 2
• Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06468644Phase 2
• A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06463834Phase 2
• Nituzumab Plus Serplulimab Combined With SBRT in Cervical CancerRecruitingNCT06455072Phase 2
• Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical CancerRecruitingNCT06455046Phase 2
• Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKINot yet recruitingNCT06441045Phase 2
• Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT06331845Phase 2
• Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal InjuryRecruitingNCT06325982Not applicable
• Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLCEnrolling by invitationNCT06260553Phase 2
• The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian CancerNot yet recruitingNCT06242392
• A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver MetastasesNot yet recruitingNCT06218888Phase 2
• SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06208033Early Phase 1
• Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric CancerNot yet recruitingNCT06197438Phase 2
• MRI-based Signatures for Survival Prediction in Cervical Cancer With RadiotherapyNot yet recruitingNCT06197126
• Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical CancerNot yet recruitingNCT06149767Phase 2
• Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical CancerRecruitingNCT06140589
• Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of LifeNot yet recruitingNCT06136962
• Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung CancerRecruitingNCT06136910Phase 1/2
• MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial CancerNot yet recruitingNCT06126393
• A Predictive Model for Early Metastasis in Cervical Cancer Patients After RadiotherapyNot yet recruitingNCT06101966
• Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPCNot yet recruitingNCT06095167Phase 3
• CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal CarcinomaRecruitingNCT06095154Phase 3
• PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid TumorsNot yet recruitingNCT06078670Phase 1/2
• Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial CancerNot yet recruitingNCT06066216Phase 2
• A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical CancerNot yet recruitingNCT06039982
• An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant MelanomasEnrolling by invitationNCT05928962Phase 1
• XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell CarcinomaNot yet recruitingNCT05927844Phase 1
• Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal TumorsNot yet recruitingNCT05922358Phase 2
• Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and CisplatinRecruitingNCT05910177Phase 2
• A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker AnalysesNot yet recruitingNCT05897138Phase 2
• Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingNCT05882630Phase 1/2
• HRQOL in Locally Advanced Thyroid CarcinomaRecruitingNCT05824312
• Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.RecruitingNCT05753826Phase 2
• Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric CancerNot yet recruitingNCT05751265Phase 2
• Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerRecruitingNCT05699655Phase 2/3
• Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant MelanomaNot yet recruitingNCT05664139Phase 2
• TIL Cells for the Treatment of the Advanced Solid Tumors PatientsNot yet recruitingNCT05649618Early Phase 1
• TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid TumorsNot yet recruitingNCT05648994Early Phase 1
• The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard TherapyNot yet recruitingNCT05640726Phase 2
• Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal CancerNot yet recruitingNCT05628610Phase 2
• Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.RecruitingNCT05624099Phase 2
• Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerNot yet recruitingNCT05597527Phase 2
• Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung CancerNot yet recruitingNCT05595889Phase 2
• Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International GuidelinesNot yet recruitingNCT05519956Phase 3
• Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal CancerNot yet recruitingNCT05479240Phase 2
• Phase I/II Study of the Combination of Irinotecan and POF (POFI) and TislelizumabRecruitingNCT05319639Phase 1/2
• Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast CancerRecruitingNCT05019690Phase 1/2
• A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal TumorsActive, not recruitingNCT07104877Not applicable
• The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric JunctionStatus unknownNCT06396585Phase 2
• Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal CancerCompletedNCT06333769Phase 2
• Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular CarcinomaStatus unknownNCT06061445Not applicable
• A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).Active, not recruitingNCT05953909
• Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal CancerStatus unknownNCT05839470Phase 2
• Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal CancerStatus unknownNCT05799443Phase 2
• Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung AdenocarcinomaStatus unknownNCT05675033Phase 2

← Fujian Cancer Hospital overview and focus areas